Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe disease
Alison McVie‐Wylie, Robert J. Mattaliano, M. W. O'CALLAGHAN, William M. Canfield(Winthrop-University Hospital), Russell Gotschall, Nina Raben(National Institutes of Health), K.L. Lee, Hung Do, Beth L. Thurberg(Sanofi (United States)), Xin Jin, Laura Andrews, J M McPherson, Hengheng Qiu, Chris Rogers
Cited by 96
Related Papers
Anticoagulant properties of bovine plasma protein C following activation by thrombin
|Biochemistry|1977|491
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
|EMBO Molecular Medicine|2013|337
Cloning and Expression of Human Core 1 β1,3-Galactosyltransferase
|Journal of Biological Chemistry|2002|291
Pompe Disease: From Basic Science to Therapy
|Neurotherapeutics|2018|230
Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients
|Kidney International|1997|219